Completed PHASE2 INTERVENTIONAL 2-arm NCT04890509

A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients

A Multicentre, Phase 2, Randomised Study to Assess the Efficacy and Safety of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients

Sponsor: BerGenBio ASA

Conditions COVID-19

Interventions Bemcentinib SoC

Updated 5 times since 2021 Last updated: Oct 14, 2024 Started: Oct 20, 2020 Primary completion: May 25, 2021 Completion: May 25, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04890509, this PHASE2 trial focuses on COVID-19 and remains completed. Sponsored by BerGenBio ASA, it has been updated 5 times since 2020, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Nov 2024 — Present [monthly]

Completed PHASE2
Sep 2024 — Nov 2024 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Nov 2021 — Jul 2024 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Jun 2021 — Nov 2021 [monthly]

Active Not Recruiting PHASE2

First recorded

Oct 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

BerGenBio ASA

Data source: BerGenBio ASA

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bellville, South Africa , Groenkloof, South Africa , Mangalore, India , Mowbray, South Africa , Mysuru, India , Nashik, India , New Delhi, India , Pune, India , Secunderabad, India , Somerset West, South Africa and 2 more locations